Does Infliximab Infusion Impact Results of Operative Treatment for Crohn's Perianal Fistulas?
Authors:
- Wolfgang B. GaertnerWGWolfgang B. Gaertner
- Alejandra DecaniniADAlejandra Decanini
- Anders MellgrenAMAnders Mellgren
- Ann C. LowryALAnn C. Lowry
- Stanley M. GoldbergSGStanley M. Goldberg
- Robert D. MadoffRMRobert D. Madoff
- Michael P. SpencerMSMichael P. Spencer
- 1 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 50 (11) , 1754-1760
Abstract
Infliximab is an effective treatment for active intestinal Crohn's disease; however, the efficacy of infliximab in perianal Crohn's disease is controversial. This study was designed to compare patients with Crohn's disease who underwent perianal fistula surgery with or without infliximab infusion. A retrospective chart review of 226 consecutive patients with Crohn's disease who underwent operative treatment with or without infliximab (3-6 infusions of 5 mg/kg) from March 1991 through December 2005 was completed. Patients were classified as completely healed, minimally symptomatic (seton placement with minimal drainage and/or infliximab dependence), and failure (persistent or recurrent symptomatic fistula, diverting procedure, or proctectomy). A total of 226 patients underwent operative treatment alone (n = 147) or in combination with infliximab infusion (n = 79). Age, gender, and preoperative history of intestinal and perianal Crohn's disease were similar between groups. Mean follow-up was 30 (range, 6-216) months. Operative treatment consisted of seton drainage (n = 112), conventional fistulotomy (n = 92), fibrin glue injection (n = 14), advancement flap (n = 5), collagen plug insertion (n = 2), and transperineal repair (n = 1). Eighty-eight patients (60 percent) healed completely with operative treatment alone, and 47 patients (59 percent) healed after operative treatment in combination with infliximab (P = not significant). Operative treatment of perianal fistulas in patients with Crohn's disease resulted in complete healing in approximately 60 percent of patients. Preoperative infliximab infusion did not affect overall healing rates.Keywords
This publication has 42 references indexed in Scilit:
- Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton PlacementInflammatory Bowel Diseases, 2003
- The natural history of fistulizing Crohn's disease in Olmsted County, MinnesotaGastroenterology, 2002
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Tumour necrosis factor and Crohn's disease.Gut, 1997
- Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's diseaseJournal of Clinical Immunology, 1996
- Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel diseaseGastroenterology, 1994
- Cytokines (Immunoinflammatory Hormones) and Their Natural Regulation in Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis): A ReviewDigestive Diseases, 1994
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Seton treatment of high anal fistulaeBritish Journal of Surgery, 1991
- Anorectal crohn's disease: Definitive surgery for fistulas and recurrent abscessesThe American Journal of Surgery, 1980